Showing results (201-210 of 229) with videos related to

Sort By:
Pageof 23
Breast Cancer Research and Treatment|August 10, 2007
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancerP Neven, B Van Calster, I Van den Bempt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IK N Moore, A M Oza, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trialH Blons, J Abdelli, S Landman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysisS I Labidi-Galy, M Rodrigues, J L Sandoval, et al.
Anti-Cancer Drugs|March 23, 2001
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group StudyF Duffaud, M E van der Burg, M Namer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2018
Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countriesG Oskay-Özcelik, S Alavi, R Richter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialE Pujade-Lauraine, F Selle, G Scambia, et al.
European Journal of Gynaecological Oncology|August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of CancerH C Wagenaar, S Pecorelli, I Vergote, et al.
Pageof 23